<DOC>
	<DOC>NCT00562913</DOC>
	<brief_summary>Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients</brief_summary>
	<brief_title>Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>At least 18 years old Advanced histological or cytological documentation of cancer lifeexpectancy of at least 12 weeks able to swallow pills ECOG status of 0,1 or 2 adequate bone marrow liver and renal function &gt; NYHA Class 2 CHF Serious myocardial dysfunction, or symptomatic coronary artery disease (MI more than 6 months prior to study entry is allowed) History of organ allograft uncontrolled hypertension renal dialysis Bleeding event/hemorrhage within 4 weeks of study treatment major surgery within 4 weeks of study treatment Previous exposure to doxorubicin or other anthracyclines exceeding a maximum lifetime cumulative dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
</DOC>